Background: Transcatheter aortic valve implantation/replacement (TAVI/TAVR) is becoming more frequently used to treat aortic stenosis (AS), with increasing push for the procedure in lower risk patients.
Introduction
As Western populations age, the prevalence of aortic stenosis (AS) is gradually increasing (1) . In a select population, surgical aortic valve replacement (SAVR) is precluded by patient frailty and other comorbidities (2) . The availability of transcatheter aortic valve implantation/ replacement (TAVI/TAVR), pioneered in the early 2000s, has made a significant impact on survival for these patients (3) (4) (5) . These early successes led to a number of trials, such as the PARTNER and US Pivotal trials, which compared TAVI, SAVR and standard treatment outcomes ( Figure 1) . As a result, TAVI is increasingly being considered as a less-invasive option for treatment of AS in younger and lower surgical risk patients, where SAVR is not necessarily contraindicated (6, 7) , although this is not without controversy (8) .
While the short-term outcomes of TAVI have been well explored, limited studies have examined longer term results (9, 10) . Additionally, while much data has been published on SAVR survival beyond 5 years, there are relatively few studies (outside the Edwards and Medtronic trials) that present long-term, two-armed results with TAVI and SAVR. The present review aims to identify and analyze survival outcomes of studies which present 5-year of follow-up.
Methods

Literature search
Electronic searches were performed on Medline, Scopus and PubMed from dates of database inception to June 2017 using ("transcatheter aortic valve implantation" OR "transcatheter aortic valve replacement" OR "TAVI" OR "TAVR") AND ("survival" OR "long-term" OR "KaplanMeier"), either as keywords or MeSH headings. Records were systematically reviewed according to the inclusion and exclusion criteria by two independent authors (Adam Chakos, Ashley Wilson-Smith). A PRISMA diagram of the search process is presented in Figure S1 .
Inclusion/exclusion criteria
Studies were included if 20 or more patients underwent TAVI (via any access approach and as a stand-alone or concomitant procedure), and where follow-up was for at least five years. Time-to-event data was required to be present in order to facilitate statistical analysis. NonEnglish studies, review articles, conference abstracts, editorials, letters, case reports and opinions were excluded. Only the most up-to-date study was included if duplicating studies were published for the same patient cohort.
Quality assessment of included studies
A modified quality appraisal schema, based on the Canadian National Institute of Health's Quality Assessment Tool for Case Series Studies, was used to evaluate all included studies (11). In short, studies were scored based on six main domains: clarity of objective, characteristics of the study population, description of the intervention, adequate outcome measures, suitable statistical analysis, and appropriate results/conclusions (quality is listed in Table S1 ). Studies were scored out of 16 points. Studies scoring 13-16 were categorized as high-quality, 10-12 medium-quality and below 10 were low-quality.
The primary outcome of interest is time-to-event survival data. Secondary outcomes of interest included short-term outcomes such 30-day mortality, 30-day stroke/ CVA, permanent pacemaker (PPM) implantation and acute kidney injury (AKI). Definitions from the Valve Academic Research Consortium (VARC)-2 consensus were used where appropriate (12) . Logistic EuroSCORE (LES) was recorded in preference to additive EuroSCORE and EuroSCORE II since the former was replaced by the logistic model and the latter was not widely reported as it has only been in use since 2012.
Statistical analysis
Baseline patient data, risk factors, operative details and operative outcomes were extracted by two independent researchers. Kaplan-Meier curves were digitized and iteratively computed to generate individual patient data, using the algorithm from Guyot and colleagues (13) . Censoring was assumed to be constant unless the particular curve had a long follow-up of only minimal patients (in which case, censoring was manually entered). The death event and censoring data for the entire cohort was pooled and an overall survival curves calculated according to the Kaplan-Meier method using MATLAB R2016a [Natick, Massachusetts, US (14) ]. Survival was also compared to the general population by utilizing life tables obtained from government sources specific to the majority of patients within the included studies (15) (16) (17) . Specifically, weighted survival (according to patient numbers) for Italy, UK, Germany, Canada, US and Spain were used, accounting for © Annals of Cardiothoracic Surgery. All rights reserved.
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Results
Overall 5,194 records were identified in the literature search. Following application of the inclusion and exclusion criteria, 31 studies were included for analysis, with a total of 13,857 patients. The median number of patients per study was 120 (interquartile range 60-292) with median followup of 5 years (interquartile range 5-6 years, mean follow-up 5.6 years). These studies included 23 single-center studies (6, 10, ) and 8 multi-center studies (39) (40) (41) (42) (43) (44) (45) (46) , where 14 were retrospective and 15 had prospective enrolment. The studies were conducted in the UK, Italy, Germany, US, Canada, Spain, Israel, Denmark and Sweden. Seven studies were deemed high-quality studies, 19 as medium-quality and 5 as low-quality. Kaplan-Meier survival for patients in the three study groups was calculated and results are presented in Figure S2 .
The mean age for the entire cohort was 81.5±7.0 years, with 45.7% males. Pre-operative LES was the most widely available risk statistic among included studies, reported for 91% of the total cohort, with a mean value of 22.1%±13.7%. Pre-operative Society of Thoracic Surgeons (STS) score was reported for 50% of the cohort at a mean risk value of 9.17%±6.61%. Baseline characteristics and comorbidities (such as hypertension, LVEF%, cardiac history and interventions) recorded across more than half of the included studies are summarized in Table 1 and fully detailed in Table S2 .
Multiple types of valves were used, which was reported by 84% of studies. For those studies which specified valve type, 64.7% of reported patients received an Edwards valve (Sapien, Sapien XT, Sapien 3), 33.5% received a Medtronic valve (CoreValve, Evolut R) and 1.7% of patients received a different type (Lotus or JenaValve). Valve delivery approach was specified for 92% of included patients. Where specified, 68.5% of approaches were transfemoral, 34.8% were transapical, 2.6% were trans-subclavian and 1.9% were trans-aortic (and other) approach type.
Aggregated survival rates at 1-, 2-, 3-, 5-, and 7-year were 83%, 75%, 65%, 48%, and 28%, respectively. The overall survival curve derived from reconstructed individual patient data is shown in Figure 2 . Patients were further grouped according to their LES as either moderate (LES ≤20) or high-risk (LES >20) and the respective results are shown in Figure 3 . Risk factors and outcomes reported in more than half of the included studies were included for analysis in this review -a summary is presented in Table 1 . Kaplan-Meier curves generated for high-, medium-, and low-quality studies are presented in Figure S2 .
Post-operative 30-day mortality was 8.4% (12,913 patients). Other widely reported post-operative outcomes included incidence of 30-day cerebrovascular accident (2.8% of 10,881 patients), AKI (14.4% of 7,963 patients) and requirement for PPM implantation (13.4% of 11,599 patients). Other operative and post-operative details were insufficiently presented to facilitate statistical analysis (Table S3) .
Discussion
TAVI trials, expanding indications and criticisms
Since introduction in 2002, TAVI has been used at increasing rates, with over one-hundred thousand procedures performed worldwide (47) . Much of the clinical outcomes have been captured in a range of trials and registries, including the Edwards-sponsored PARTNER trials, Medtronic-sponsored Pivotal and SURTAVI trials, UK TAVI registry (UK), GARY registry (Germany), OBSERVANT registry (Italy) and NOTION trial (Norway) (3, (48) (49) (50) (51) (52) (53) (54) .
In 2011, the seminal PARTNER IA and IB randomized controlled trials, using Edwards' balloon-expandable valve, established the non-inferiority of TAVI compared to SAVR and the superiority of TAVI compared to medical management (55) . These favorable results energized TAVI advocates, with more studies subsequently commenced. The validation of the Edwards valve encouraged Medtronic to develop their model, with similarly favorable results from their Pivotal RCT subsequently published in 2014 (50) . Both trials recruited high-risk patients (or non-surgical candidates in PARTNER IB), establishing the clinical legitimacy of utilizing TAVI in these patients (34, 56) . Despite early differences in TAVI and SAVR outcomes seen in the PARTNER IA trial, at five-years these differences have dissipated. However, TAVI's higher rate of vascular complications and paravalvular leak persisted at five years, raising concerns. SAVR patients in PARTNER I had higher rates of major bleeding post-operatively and in the long term (34, 49, 56, 57) .
Like PARTNER IA, the three-year follow-up of the US Pivotal trial (again with a 7.5% difference required for inferiority) found similar mortality between SAVR and TAVI, the same issues of vascular complications and valvular regurgitation (including para-valvular leak) and reported higher incidence of re-intervention in TAVI. SAVR patients in the Pivotal trial also had higher rates of major bleeding and AKI compared to TAVI. Unlike the Edwards valve, significant need for PPM implantation compared to SAVR persisted at three years in the CoreValve trial (58) . Neither product demonstrated valvular deterioration at late follow-up, allaying early concerns regarding the longterm durability of TAVI valves due to device crimping for implantation (59) .
Given the success demonstrated by the PARTNER I and US Pivotal trials, TAVI procedure rates increased (49, 51) . The NOTION trial in Norway also examined TAVI mortality in lower risk groups by virtue of its "all comers" nature. That RCT used the same 1:1 randomization for 280 patients receiving TAVI and SAVR and patients had a mean STS score of 3.0%±1.7%. The CoreValve was used and like the US Pivotal and SURTAVI trials, no statistically significant difference in mortality, stroke, or MI at 2 years between methods was found. Complications with respect to TAVI and SAVR were the same as the Pivotal and SURTAVI trials (52, 60, 61) .
Results of the PARTNER II trial raised concern over whether the findings of these RCTs reflect real-world outcomes, and whether it can potentially introduce bias in favor of TAVI. Some criticism of the PARTNER II trial raised concerns that treatment in the SAVR arm was not representative of current surgical practices and included undetailed concomitant interventions, although 15% of the SAVR cohort did undergo contemporary SAVR with a minimally invasive approach. However, it should be noted that the SAVR cohort also included patients that underwent concomitant mitral or tricuspid repair or coronary grafting (62) .
A new generation of Edwards and Medtronic valves have now been launched (Sapien 3 and EVOLUT R, respectively) and the PARTNER 3 and US clinical trial NCT02701283 RCTs are presently recruiting to investigate their use in low operative mortality risk patients (STS <4% for PARTNER 3, risk of mortality <3% at 30 days for Medtronic RCT) (63, 64) . Earlier studies also studied TAVI beyond the context of calcific AS, in pure aortic regurgitation patients (65, 66) , bicuspid aortic valve and (as in a number of our included studies) valve-in-valve for both redo-TAVI or SAVR (6, 25, 32, 67, 68) .
TAVI is undoubtedly growing in usage across the world and as the results of these newer generation trials become available and potentially address earlier concerns, TAVI will inevitably be applied
Cost effectiveness of TAVI
In addition to demonstrating the clinical effectiveness of TAVI, much has been published on its cost-effectiveness and financial sustainability for widespread adoption. These studies have used methods such as incremental cost effectiveness ratio (ICER), decision-analytic and Markov models to compare TAVI to SAVR and standard treatment. Analysis in the context of a government health system (the UK NHS) using data from the PARTNER I trials and extrapolated into the future calculated TAVI to cost anywhere from 2-5 times that of medical management (70, 71) but highlighted that TAVI achieves markedly better survival outcomes. Quality-adjusted life-years (QALY) analysis of PARTNER I and other national registries demonstrated that TAVI still fell within the cost limits set by the NICE guidelines used under the NHS and thus, is a suitable (and superior) treatment to medical management in the case of inoperable AS (70) (71) (72) (73) .
While TAVI has been evaluated as cost-effective in patients who are not candidates for surgery, it has yet to be shown to be financially sustainable in high-risk patients who can undergo a much more economical surgical AVR procedure. A significant driver of the cost-difference between SAVR and TAVI is the high device cost compared to surgical valves (74) . When the cost of the device is discounted from the analysis, TAVI becomes comparable to SAVR, owing particularly to the reduced intensive care unit and hospital stay required for TAVI (42) . It has also been noted that TAVI requires more extensive diagnostic workup (2), which may further offset the benefit of reduced hospital stay. Additionally, it is not clear whether all cost analyses accounted for costs associated with the higher reintervention and re-admission rates of TAVI compared to © Annals of Cardiothoracic Surgery. All rights reserved.
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Long-term outcomes
A key factor in adoption of any new surgical procedure or device is its long-term efficacy. While the short-term results have been well studied, limited data exists regarding long-term outcomes following TAVI. The present review of nearly 14,000 cases found survival at 5 years to be 48%. When compared against the actuarial survival of 82-yearold, the aggregated results demonstrate poorer survival outcomes and a marginally worse Kaplan-Meier rate (after the initial attrition in the first year post-operatively). Mack and colleagues followed a small cohort of nonagenarians receiving TAVI in the US and found that their survival at 5 years to be approximately 30%, which was consistent with the expected age-and sex-matched actuarial survival in this elderly cohort (33) .
Limitations
Firstly, a wide range of TAVI models and generations were included in the present analysis, which could not be accounted for. Secondly, the data presented in this review included series from the early TAVI era, where the learning curve associated with the uptake of this technology could have influenced these results. The likely evolution of patient selection, the procedure itself, and post-operative management is likely to have had an effect on survival outcomes in contemporary TAVI applications. It is also acknowledged that the heterogeneity in patient selection and procedural variations may have also affected outcomes. Finally, the method used to re-construct patient data from Kaplan-Meier survival curves assumed constant censoring and this may have impacted on the computed patient data.
Conclusions
It is widely anticipated that as results of newer generation device trials become available, TAVI will be applied in a broader context to lower risk patients. As TAVI registries continue to mature and grow, particularly all-comers registries like the UK TAVI registry, a clear case profile for TAVI may be brought in to focus. Additionally, as newer valve designs and device manufacturers enter the market, the economic case for TAVI will undoubtedly improve. However, future cost analyses must be included the procedural workup and long-term follow-up treatments. Despite the aggregated results identified in the present analysis, it is abundantly clear that extended data is required to clarify the long-term outcomes of TAVI.
Expert opinion 1 (Sameer Arora, John P. Vavalle)
In this study, Chakos and colleagues report an exhaustive aggregation of studies with reported follow-up of 5 years or more after TAVR. The aggregated survival at 5-and 7-year follow-up after TAVR was 48% and 28%, respectively. The study population largely represents a high-surgical risk category with more than 80% of the patients at highsurgical-risk with the mean STS >9. Additionally, most of the included studies were of initial experiences of TAVR, and therefore, do not take into consideration the improvements in prostheses and operator experiences in recent years. However, this study provides a benchmark for the more recent TAVR experiences and will help us to evaluate if improvements in prostheses performance and operator experiences has led to improvement in overall outcomes, which we expect it has.
In the US, TAVR is now recommended for patients with severe AS and high or inoperable-surgical risk, and is an alternative to surgery for intermediate-risk patients. Although the authors found a reduced survival for post-TAVR patients when compared to a general population of similar mean age, this does not take into account the comorbidities that made the patient high or extreme risk for surgery. This highlights the overall morbidity of many of these patients undergoing TAVR, and supports the notion that a less invasive approach is favored for this group.
This study now helps set the stage for the next frontier of TAVR-low surgical risk patients. As we move towards an "all-comers" treatment paradigm for TAVR, there are several important unanswered questions. These include durability of the valve, higher rates of PPM, paravalvular leak, and long-term survival. As we await the results of the randomized trials of low risk patients, this study provides further support to pushing the envelope towards low risk. One thing is certain, TAVR is here to stay, and its rapid growth will only accelerate; however, we must use caution to not expand its use to low risk patients until we are certain of the long-term outcomes.
In the study, Chakos and colleagues present data on TAVI survival from 31 studies involving 13,857 patients. The authors found that the aggregated survival rates at 1-, 2-, 3-, 5-, and 7-year were 83%, 75%, 65%, 48%, and 28%, respectively. The mean age of the study population was 82 years. When compared to the actuarial survival of an 82-year-old healthy person, survival post-TAVI was poorer. This study represents the first systematic review of TAVI investigating long-term actuarial survival. The authors should be congratulated for their novel approach in exploring TAVI durability compared against an actuarial cohort. The authors further stratified patients into intermediate and high-risk categories. Expectedly, high risk patients experienced worse survival. These findings raise a question on widespread global acceptance of TAVI. It is to be noted that the present study included only registries and studies with longer term follow up, which included mostly high-risk patients with mean STS score of 9.17%±6.61%. Some of the patients included were treated as early as 2005, likely with the 1st generation TAVI devices.
The PARTNER 1B (inoperable) study that included patients with mean age of 83 years and mean STS of 11.7% showed 5-year mortality of 93.6% in medically managed patients, and 71.8% in TAVI group (56) . The risk of death at 5 years was 67.8% in the TAVI group compared with 62.4% in the SAVR group (hazard ratio 1.04, P=0.76) in the PARTNER 1A (high risk) cohort (34) . Additionally, a Mayo Clinic study showed that the asymptomatic patients with severe AS has 5-year mortality of 43% irrespective to whether they undergo SAVR. The same study also found that the 1-, 2-, and 5-year probabilities of remaining free of surgery or cardiac death were 80%, 63% and 25%, respectively (75) . These high-quality data suggest that AS is a potentially fatal disease if left untreated, and mortality remains high even if the patient is treated.
The findings of this study should raise the question of global TAVI acceptance without better quality data supporting durability. This is particularly true as TAVI evolves into intermediate and lower risk cohorts where durability data is scant. Longer term follow-up data from randomized intermediate and low risk PARTNER and CoreValve trials will potentially shed light on the durability of this technology. Until then, it is prudent to step back and continue to actively reexamine the evidence for TAVI.
Expert opinion 3: taking two birds (durability and lower risk) with one stone (younger patients): next TAVI challenge (Giuseppe Tarantini) TAVR has rapidly become the treatment of choice for AS patients at extreme or high surgical risk, and the results of recent randomized trials have now broadened TAVR indications to lower risk subjects. Nevertheless, the common risk scores used in clinical practice are accurate to predict the outcome of patients treated surgically but not by TAVI (1). The point is why? Unlike surgical series (76) , in TAVI series, the progressive decrease in mean risk score value across studies is not paralleled by a significant change in TAVR patients mean age, which steadily remained above 80 years. Data on younger patients are lacking and is difficult to find. In ongoing trials, the entry criteria remain with the heart team. Considering the previously reported disconnection between risk and age-I would expect to see data still related on patients older than 80 years.
Granted that, in our opinion, future TAVR research should concentrate on outcomes of younger patients. Performing TAVR in <75-year-old subjects will allow us to get the eagerly awaited data on prostheses durability, which remains the last strong argument against transcatheter therapy. This, of course, has to be done by means of randomized controlled trials against SAVR. However, in order to compete with the excellent results of SAVR in younger patients, TAVR has to guarantee a 30-day mortality and stroke-rate around 1%, major vascular complications rate <3%, and new PM implantation rate <10%. Furthermore, the hemodynamic performance of transcatheter devices in the setting of bicuspid AS has to improve (especially in terms of paravalvular leakage), since this anatomical finding will dramatically increase in frequency as we move to younger subjects.
TAVR has walked a long and exciting road since the first patient was treated in 2002, but there is still much to walk before we can safely and effectively offer transcatheter therapy to every AS patient.
Expert opinion 4: 'times they are a-changin' (Matthias Thielmann, Daniel Wendt)
Since TAVI has been introduced in 2002 into clinical practice, it has successfully evolved (with more than 100,000 procedures worldwide) to become a main-stream © Annals of Cardiothoracic Surgery. All rights reserved.
Ann Cardiothorac Surg 2017;6(5):432-443 www.annalscts.com therapeutic option for symptomatic patients with severe AS. Initial evidence for TAVI came from first industrysponsored clinical trials but also from several national registries considering patients who were deemed to be inoperable or non-surgical candidates as well as patients presenting with a high surgical risk. With growing experience, further developed TAVI devices and further evidence from more recent trials (although most of them still industry-initiated, -sponsored, and -controlled), the indication has and is going to shift to lower risk patients.
Aside from the euphoria around TAVI regarding its application and criticisms, the question of TAVI longterm performance and outcomes is as yet uncertain. First insights from initial randomized trials and registries were quite limited in the face of patient's age and comorbidities and present long-term data are still rare and limited in their validity and interpretation. Nevertheless, there is certainly no doubt that long-term performance and outcomes are and will become the major determinant for TAVI treatmentparticularly in the lower risk, younger patients.
The present systematic review by Chakos and colleges of long-term outcomes of TAVI encompassing nearly 14,000 TAVI patients derived from 31 worldwide studies and national registries showed an aggregated 5-year survival of 48% and a 7-year survival of 28%. This is the first systematic review of TAVI that has been investigated on long-term survival in this fashion. By comparing the actuarial survival against an age-matched population, survival post-TAVI was significantly inferior, particularly in the high-risk group. This is at first not unexpected given the patient population and comorbidities. Nevertheless, when comparing the longterm survival of SAVR with a similar age-and gendermatched population, Wendt and colleges (77) could clearly demonstrate a non-inferiority of SAVR over a similar longterm period.
Of important note, not only long-term survival, but also quality of life, incidence of repeat intervention rate, transvalvular gradients, prosthesis valve areas, and structural valve deterioration over a long-term follow-up are major important determinants which will play a key role when younger and lower risk patients are going to be considered for a TAVI treatment instead of SAVR. Therefore, much longer and lager follow-up studies are needed to objectively judge whether TAVI is superior to SAVR and should therefore be offered and recommended to a younger and lower risk patient clientele.
'And the first one now will later be last-for the times they are a-changin'-freely adapted from Bob Dylan. Figure S1 PRIMSA flow chart detailing the literature search process for TAVI outcomes at 5 years and beyond. 
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